Published in Prostate on May 01, 2009
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol (2013) 1.22
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Current status of immunological therapies for prostate cancer. Curr Opin Urol (2010) 1.06
Acute inducible ablation of GRP78 reveals its role in hematopoietic stem cell survival, lymphogenesis and regulation of stress signaling. PLoS One (2012) 0.97
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol (2012) 0.92
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012) 0.91
Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate (2010) 0.91
Update on prostate cancer vaccines. Cancer J (2011) 0.88
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81
T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate (2011) 0.80
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
New insights into androgenic immune regulation. Oncoimmunology (2014) 0.76
Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget (2017) 0.75
Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer (2017) 0.75
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97
Th17 cells in human disease. Immunol Rev (2008) 4.27
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin (1972) 3.35
Interactions between the gonadal steroids and the immune system. Science (1985) 3.15
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol (2000) 2.04
In vivo production and function of IL-12 p40 homodimers. J Immunol (1997) 1.72
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res (2005) 1.68
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol (2004) 1.47
Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol (2005) 1.43
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 1.41
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol (2001) 1.34
Concepts of activated T cell death. Crit Rev Oncol Hematol (2008) 1.33
Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol (2005) 1.26
Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci (2002) 1.25
Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol (1995) 1.19
B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol (2005) 1.13
Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev (2006) 1.12
Castration alters peripheral immune function in normal male mice. Immunology (1995) 1.12
Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex. J Immunol (1998) 1.09
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther (2005) 1.05
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 1.05
Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A (2001) 1.02
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology (2005) 1.00
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer (2005) 1.00
CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology (2007) 0.99
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother (2006) 0.98
Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol (2004) 0.93
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
NF-kappaB-dependent regulation of the timing of activation-induced cell death of T lymphocytes. J Immunol (2006) 0.92
The effect of testosterone on cytokine production in the specific and non-specific immune response. Am J Reprod Immunol (2004) 0.90
Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J Immunol (2002) 0.87
Specificity and regulation of cytotoxic T-lymphocyte responses analyzed with H-2 mutants. Transplant Proc (1983) 0.86
Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Jpn J Clin Oncol (2006) 0.85
Synergistic antitumor activity of immune strategies combined with radiation. Front Biosci (2007) 0.85
Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate. Mol Endocrinol (2004) 0.85
Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate (2000) 0.85
Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit. Curr Oncol Rep (2005) 0.83
Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82
Mechanism of skin allograft enhancement across an H-2 class I mutant difference. Evidence for involvement of veto cells. Eur J Immunol (1988) 0.82
Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol (2005) 0.79
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Disabling musculoskeletal pain in working populations: is it the job, the person, or the culture? Pain (2013) 2.38
Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med (2006) 1.90
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Using accelerometers and GPS units to identify the proportion of daily physical activity located in parks with playgrounds in New Zealand children. Prev Med (2010) 1.70
Physical and psychosocial risk factors for musculoskeletal disorders in New Zealand nurses, postal workers and office workers. Inj Prev (2010) 1.49
Child sun protection: sun-related attitudes mediate the association between children's knowledge and behaviours. J Paediatr Child Health (2008) 1.49
The CUPID (Cultural and Psychosocial Influences on Disability) study: methods of data collection and characteristics of study sample. PLoS One (2012) 1.46
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 1.41
Feasibility of forearm ultrasonography-guided nerve blocks of the radial, ulnar, and median nerves for hand procedures in the emergency department. Ann Emerg Med (2006) 1.39
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One (2012) 1.38
The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol (2002) 1.30
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood (2003) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets (2007) 1.26
The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol (2013) 1.20
Prevalence and impact of musculoskeletal disorders in New Zealand nurses, postal workers and office workers. Aust N Z J Public Health (2009) 1.18
In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res (2007) 1.16
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Patterns of multisite pain and associations with risk factors. Pain (2013) 1.12
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12
Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol (2002) 1.12
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate (2011) 1.11
AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol (2008) 1.11
Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res (2003) 1.11
Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol (2011) 1.06
Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep (2013) 1.06
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06
A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol (2009) 1.05
Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol (2005) 1.03
Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol (2007) 1.02
The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol (2011) 1.01
Maternal psychological reaction to newborn genetic screening for type 1 diabetes. Pediatrics (2007) 1.00
HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol (2003) 0.99
Rural pharmacy in New Zealand: effects of a compulsory externship on student perspectives and implications for workforce shortage. Aust J Rural Health (2008) 0.98
Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol (2007) 0.98
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol (2009) 0.98
Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem (2004) 0.96
Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine (2007) 0.95
The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res (2002) 0.95
CD4+ T cell matters in tumor immunity. Int Rev Immunol (2003) 0.93
Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol (2011) 0.93
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
Nuts improve diet quality compared to other energy-dense snacks while maintaining body weight. J Nutr Metab (2011) 0.92
Development of a nanoparticle-based influenza vaccine using the PRINT technology. Nanomedicine (2012) 0.91
Ins and outs of clinical trials with peptide-based vaccines. Front Biosci (2002) 0.91
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
A micronutrient-fortified seasoning powder reduces morbidity and improves short-term cognitive function, but has no effect on anthropometric measures in primary school children in northeast Thailand: a randomized controlled trial. Am J Clin Nutr (2008) 0.91
Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol (2002) 0.91
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res (2002) 0.91
Diet and social status on Taumako, a Polynesian outlier in the Southeastern Solomon Islands. Am J Phys Anthropol (2013) 0.90
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res (2010) 0.90
Occupational sun protection: workplace culture, equipment provision and outdoor workers' characteristics. J Occup Health (2013) 0.89
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One (2010) 0.89
Faster self-reported speed of eating is related to higher body mass index in a nationwide survey of middle-aged women. J Am Diet Assoc (2011) 0.89
Primary school sun protection policies and practices 4 years after baseline--a follow-up study. Health Educ Res (2012) 0.89
Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene (2004) 0.89
Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim (2006) 0.89
Walking to school: frequency and predictors among primary school children in Dunedin, New Zealand. N Z Med J (2008) 0.89
Emerging strategies in tumor vaccines. Curr Opin Oncol (2002) 0.89
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res (2009) 0.88
Understanding of sport concussion by the parents of young rugby players: a pilot study. Clin J Sport Med (2009) 0.88
Drinking history, current drinking and problematic sexual experiences among university students. Aust N Z J Public Health (2010) 0.88
HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci (2003) 0.88
Rendering protein-based particles transiently insoluble for therapeutic applications. J Am Chem Soc (2012) 0.88
Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res (2004) 0.87
Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. Clin Cancer Res (2007) 0.87
Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med (2007) 0.87
Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol (2014) 0.87
Suicide by occupation: does access to means increase the risk? Aust N Z J Psychiatry (2010) 0.86
Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine (2009) 0.86
Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther (2004) 0.86
Outpatient follow-up for patients with rheumatoid arthritis in relation to New Zealand Rheumatology Association guidelines at Dunedin Hospital. N Z Med J (2008) 0.86
Are pregnant women in New Zealand iodine deficient? A cross-sectional survey. Aust N Z J Obstet Gynaecol (2011) 0.86
Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett (2011) 0.85
Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med (2007) 0.85
Therapeutic vaccination for HPV induced cervical cancers. Dis Markers (2007) 0.85
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J (2010) 0.85
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother (2007) 0.85
Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol (2012) 0.84
Is sperm protein 17 a useful target for tumor immunotherapy? Blood (2003) 0.84
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med (2006) 0.84
Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother (2011) 0.84
Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med (2009) 0.84